Literature DB >> 27406250

Genotype and brain pathology phenotype in children with tuberous sclerosis complex.

Iris E Overwater1,2, Rob Swenker3, Emma L van der Ende1, Kimberley Bm Hanemaayer1, Marianne Hoogeveen-Westerveld3, Agnies M van Eeghen2,4, Maarten H Lequin5, Ans Mw van den Ouweland3, Henriëtte A Moll2,4, Mark Nellist3, Marie-Claire Y de Wit1,2.   

Abstract

Structural brain malformations associated with Tuberous Sclerosis Complex (TSC) are related to the severity of the clinical symptoms and can be visualized by magnetic resonance imaging (MRI). Tuberous Sclerosis Complex is caused by inactivating TSC1 or TSC2 mutations. We investigated associations between TSC brain pathology and different inactivating TSC1 and TSC2 variants, and examined the potential prognostic value of subdivision of TSC2 variants based on their predicted effects on TSC2 expression. We performed genotype-phenotype associations of TSC-related brain pathology on a cohort of 64 children aged 1.4-17.9 years. Brain abnormalities were assessed using MRI. Individuals were grouped into those with an inactivating TSC1 variant and those with an inactivating TSC2 variant. The TSC2 group was subdivided into changes predicted to result in TSC2 protein expression (TSC2p) and changes predicted to prevent expression (TSC2x). The TSC2 group was associated with more and larger tubers, more radial migration lines, and more subependymal nodules than the TSC1 group. Subependymal nodules were also more likely to be calcified. Subdivision of the TSC2 group did not reveal additional, substantial differences, except for a larger number of tubers in the temporal lobe and a larger fraction of cystic tubers in the TSC2x subgroup. The severity of TSC-related brain pathology was related to the presence of an inactivating TSC2 variant. Although larger studies might find specific TSC2 variants that have prognostic value, in our cohort, subdivision of the TSC2 group did not lead to better prediction.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27406250      PMCID: PMC5117934          DOI: 10.1038/ejhg.2016.85

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  32 in total

1.  Biallelic TSC gene inactivation in tuberous sclerosis complex.

Authors:  Peter B Crino; Eleonora Aronica; Gordon Baltuch; Katherine L Nathanson
Journal:  Neurology       Date:  2010-05-25       Impact factor: 9.910

2.  Prognostic significance of tuber count and location in tuberous sclerosis complex.

Authors:  Colin Doherty; Suzanne Goh; Tina Young Poussaint; Namik Erdag; Elizabeth A Thiele
Journal:  J Child Neurol       Date:  2005-10       Impact factor: 1.987

3.  Absence of subependymal nodules in patients with tubers suggests possible neuroectodermal mosaicism in tuberous sclerosis complex.

Authors:  Susana Boronat; Paul Caruso; Elizabeth A Thiele
Journal:  Dev Med Child Neurol       Date:  2014-06-21       Impact factor: 5.449

4.  Subependymal nodules and giant cell tumours in tuberous sclerosis complex patients: prevalence on MRI in relation to gene mutation.

Authors:  Caterina Michelozzi; Giovanni Di Leo; Federica Galli; Fabiane Silva Barbosa; Francesca Labriola; Francesco Sardanelli; Gianpaolo Cornalba
Journal:  Childs Nerv Syst       Date:  2012-08-31       Impact factor: 1.475

5.  Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.

Authors:  S L Dabora; S Jozwiak; D N Franz; P S Roberts; A Nieto; J Chung; Y S Choy; M P Reeve; E Thiele; J C Egelhoff; J Kasprzyk-Obara; D Domanska-Pakiela; D J Kwiatkowski
Journal:  Am J Hum Genet       Date:  2000-12-08       Impact factor: 11.025

6.  Functional assessment of variants in the TSC1 and TSC2 genes identified in individuals with Tuberous Sclerosis Complex.

Authors:  Marianne Hoogeveen-Westerveld; Marjolein Wentink; Diana van den Heuvel; Melika Mozaffari; Rosemary Ekong; Sue Povey; Johan T den Dunnen; Kay Metcalfe; Stephanie Vallee; Stefan Krueger; JoAnn Bergoffen; Vandana Shashi; Frances Elmslie; David Kwiatkowski; Julian Sampson; Concha Vidales; Jacinta Dzarir; Javier Garcia-Planells; Kira Dies; Anneke Maat-Kievit; Ans van den Ouweland; Dicky Halley; Mark Nellist
Journal:  Hum Mutat       Date:  2011-03-08       Impact factor: 4.878

7.  Intellectual ability in tuberous sclerosis complex correlates with predicted effects of mutations on TSC1 and TSC2 proteins.

Authors:  Ho Tin Wong; Deborah L McCartney; Julia C Lewis; Julian R Sampson; Christopher J Howe; Petrus J de Vries
Journal:  J Med Genet       Date:  2015-09-25       Impact factor: 6.318

8.  Identification and characterization of the tuberous sclerosis gene on chromosome 16.

Authors: 
Journal:  Cell       Date:  1993-12-31       Impact factor: 41.582

9.  The neuroanatomical phenotype of tuberous sclerosis complex: focus on radial migration lines.

Authors:  Agnies M van Eeghen; Laura Ortiz Terán; Jason Johnson; Margaret B Pulsifer; Elizabeth A Thiele; Paul Caruso
Journal:  Neuroradiology       Date:  2013-05-05       Impact factor: 2.804

10.  Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing.

Authors:  Magdalena E Tyburczy; Kira A Dies; Jennifer Glass; Susana Camposano; Yvonne Chekaluk; Aaron R Thorner; Ling Lin; Darcy Krueger; David N Franz; Elizabeth A Thiele; Mustafa Sahin; David J Kwiatkowski
Journal:  PLoS Genet       Date:  2015-11-05       Impact factor: 5.917

View more
  7 in total

1.  Re: Coexistence of Autism Spectrum Disorders Among Three Children with Tuberous Sclerosis Complex: Case reports and review of literature.

Authors:  Mahmood D Al-Mendalawi
Journal:  Sultan Qaboos Univ Med J       Date:  2017-03-30

Review 2.  The origin and natural history of autism spectrum disorders.

Authors:  James C Harris
Journal:  Nat Neurosci       Date:  2016-10-26       Impact factor: 24.884

3.  Radiobiological Characterization of Tuberous Sclerosis: a Delay in the Nucleo-Shuttling of ATM May Be Responsible for Radiosensitivity.

Authors:  Mélanie L Ferlazzo; Mohamed Kheir Eddine Bach-Tobdji; Amar Djerad; Laurène Sonzogni; Clément Devic; Adeline Granzotto; Larry Bodgi; Jean-Thomas Bachelet; Assia Djefal-Kerrar; Christophe Hennequin; Nicolas Foray
Journal:  Mol Neurobiol       Date:  2017-08-07       Impact factor: 5.590

4.  Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin.

Authors:  Pike-See Cheah; Shilpa Prabhakar; David Yellen; Roberta L Beauchamp; Xuan Zhang; Shingo Kasamatsu; Roderick T Bronson; Elizabeth A Thiele; David J Kwiatkowski; Anat Stemmer-Rachamimov; Bence György; King-Hwa Ling; Masao Kaneki; Bakhos A Tannous; Vijaya Ramesh; Casey A Maguire; Xandra O Breakefield
Journal:  Sci Adv       Date:  2021-01-08       Impact factor: 14.136

5.  GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms.

Authors:  Daniela C Salles; Kaushal Asrani; Juhyung Woo; Thiago Vidotto; Hans B Liu; Igor Vidal; Andres Matoso; George J Netto; Pedram Argani; Tamara L Lotan
Journal:  J Pathol       Date:  2022-03-29       Impact factor: 9.883

6.  A case report of severe tuberous sclerosis complex detected in utero and linked to a novel duplication in the TSC2 gene.

Authors:  Valérie Mongrain; Nicolaas H van Doesburg; Françoise Rypens; Catherine Fallet-Bianco; Justine Maassen; Julien Dufort-Gervais; Lucie Côté; Philippe Major
Journal:  BMC Neurol       Date:  2020-09-01       Impact factor: 2.474

Review 7.  The Most Common Lesions Detected by Neuroimaging as Causes of Epilepsy.

Authors:  Bożena Adamczyk; Karolina Węgrzyn; Tomasz Wilczyński; Justyna Maciarz; Natalia Morawiec; Monika Adamczyk-Sowa
Journal:  Medicina (Kaunas)       Date:  2021-03-22       Impact factor: 2.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.